Keros Therapeutics Inc (OQ:KROS)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 99 Hayden Ave Ste 120 (Bld E
Tel: 1-646-3782936
IR: See website
Key People
Jasbir Seehra
Chief Executive Officer, Director
Keith C. Regnante
Chief Financial Officer
Jennifer Lachey
Chief Scientific Officer
Claudia Ordonez
Chief Medical Officer
Business Overview
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressive. KER-047 is in a Phase I clinical trial. Its KER-012 is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
Financial Overview
For the nine months ended 30 September 2020, KerosTherapeutics Inc revenues decreased from $7.5M to $0K. Netloss applicable to common stockholders excludingextraordinary items increased from $10.9M to $35.9M.Revenues reflect a decrease in demand for the Company'sproducts and services due to unfavorable market conditions.Higher net loss reflects Research and development -Balancing val increase of 77% to $23.4M (expense).
Employees: 32 as of Sep 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $1,658M as of Sep 30, 2020
Annual revenue (TTM): $2.50M as of Sep 30, 2020
EBITDA (TTM): -$35.83M as of Sep 30, 2020
Net annual income (TTM): -$37.27M as of Sep 30, 2020
Free cash flow (TTM): -$34.65M as of Sep 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 23,175,730 as of Nov 17, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.